Skip to main content

Advertisement

SpringerLink
Log in

Movement disorders in 2016

Progress in Parkinson disease and other movement disorders

  • Year in Review
  • Published:

From Nature Reviews Neurology

View current issue Sign up to alerts

In the field of movement disorders, areas that have seen important advances in 2016 include the pathogenesis of Parkinson disease involving extra-CNS α-synuclein pathology, treatment of hyperkinetic disorders with novel dopamine-depleting drugs, and MRI-guided ultrasound surgery for the treatment of essential tremor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Mechanism of action of VMAT2 inhibitors.

References

  1. Deweerdt, S. Parkinson's disease: 4 big questions. Nature 538, S17 (2016).

    Article  CAS  PubMed  Google Scholar 

  2. Thenganatt, M. A. & Jankovic, J. Parkinson disease subtypes. JAMA Neurol. 71, 499–504 (2014).

    Article  PubMed  Google Scholar 

  3. Marras, C. & Chaudhuri, K. R. Nonmotor features of Parkinson's disease subtypes. Mov. Disord. 31, 1095–1102 (2016).

    Article  CAS  PubMed  Google Scholar 

  4. Sampson, T. R. et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell 167, 1469–1480 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Unger, M. M. et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls. Parkinsonism Relat. Disord. 32, 66–72 (2016).

    Article  PubMed  Google Scholar 

  6. Gibbons, C. H., Garcia, J., Wang, N., Shih, L. C. & Freeman, R. The diagnostic discrimination of cutaneous α-synuclein deposition in Parkinson disease. Neurology 87, 505–512 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Deng, H. X. et al. Identification of TMEM230 mutations in familial Parkinson's disease. Nat. Genet. 48, 733–739 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Huntington Study Group. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA 316, 40–50 (2016).

  9. Jankovic, J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin. Pharmacother. 17, 2461–2470 (2016).

    Article  CAS  PubMed  Google Scholar 

  10. Elias, W. J. et al. A randomized trial of focused ultrasound thalamotomy for essential tremor. N. Engl. J. Med. 375, 730–739 (2016).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Joseph Jankovic is at the Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, 7200 Cambridge, Suite 9A, Houston, Texas 77030–4202, USA.,

    Joseph Jankovic

Authors
  1. Joseph Jankovic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph Jankovic.

Ethics declarations

Competing interests

J.J. has received research and/or training grants from the Michael J. Fox Foundation for Parkinson Research, the NIH, Neurocrine Biosciences, Prothena Biosciences and Teva Pharmaceuticals. He has served as a consultant or as an advisory committee member for Allergan, Pfizer and Teva Pharmaceuticals.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jankovic, J. Progress in Parkinson disease and other movement disorders. Nat Rev Neurol 13, 76–78 (2017). https://doi.org/10.1038/nrneurol.2016.204

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2016.204

  • Springer Nature Limited

This article is cited by

Search

Navigation